Eric Aviles, MD
Cardiovascular Disease · Cayey, PRNPI 1093818924
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Boston Scientific at 36.0% of the total. Reporting peaked in 2023 at $6,917 and has fallen 55.9% since, to $3,048 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $70.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- Edwards Lifesciences$5K
- Abbott$4K
- Pfizer$2K
- Medtronic$1K
- Boehringer Ingelheim$1K
- plus $2K from 10 others
What the payments were for
- Consulting fees$1,7508%
- Speaking & faculty fees$8,65039%
- Travel & lodging$3,22415%
- Food & beverage$8,47738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 36 | $7,961 |
| Edwards Lifesciences | 52 | $4,611 |
| Abbott | 61 | $3,641 |
| Pfizer | 2 | $1,921 |
| Medtronic(2 entities) | 40 | $1,170 |
| Boehringer Ingelheim | 40 | $1,114 |
| Amgen | 31 | $651 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $311 |
| Merck | 9 | $223 |
| AstraZeneca | 10 | $208 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Siemens Medical Solutions USA, Inc. | 1 | $83 |
| Bayer Puerto Rico Inc. | 2 | $43 |
| Bridgebio Pharma, Inc. | 1 | $40 |
| PBG Puerto Rico LLC | 1 | $19 |
| Pfizer Pharmaceuticals LLC | 3 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$2,241
- WATCHMAN Access System$2,000
- VYNDAQEL$1,921
- Watchman$1,875
- VIGILANT X4 CRT-D$1,500
- Xience V coronary stent system$1,400
- PASCAL$1,075
- MitraClip System$227
- CoreValve Evolut$225
- CryoConsole$170
- AMPLATZER AMULET$160
- MitraClip$114
- PulseSelect$106
- PORTICO$102
How this compares
$22,102 in reported general payments places this provider in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 44 | $1,005,758 |
| JardianceEmpagliflozin | 551 | $371,218 |
| EntrestoSacubitril/Valsartan | 516 | $354,408 |
| EliquisApixaban | 555 | $344,559 |
| FarxigaDapagliflozin Propanediol | 547 | $333,552 |
| CamzyosMavacamten | 22 | $181,900 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 158 | $95,816 |
| Repatha PushtronexEvolocumab | 123 | $75,984 |
| XareltoRivaroxaban | 119 | $67,655 |
| BrilintaTicagrelor | 118 | $54,632 |
| Repatha SureclickEvolocumab | 78 | $44,016 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 365 | $28,808 |
| Candesartan Cilexetil | 426 | $26,423 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $22,191 |
| JanuviaSitagliptin Phosphate | 38 | $21,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $1,921 | $1,350,316599 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta, Synjardy | $1,114 | $518,752798 claims |
| AstraZenecaFarxiga, Brilinta | $208 | $388,184665 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $89 | $181,90022 claims |
| MerckJanumet, Januvia, Janumet Xr | $223 | $64,100119 claims |
| AmgenCorlanor | $651 | $4,00012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Cayey
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Luis Renta RosaCarolina$83K
- Ramon PereaSan Juan$68K
- Denis Ruiz SerranoGuaynabo$66K
- Francisco Merced-OrtizSan Juan$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.